INNOVATIVE DRUGS FOR SEVERE WOUND-HEALING PROBLEMS AND GLAUCOMA

Reto Naef, PhD, MBA
CEO and founder
The company

Founded: 2009 GmbH, 2015 AG
Headquarter: Schlieren, Switzerland
Employees: 15

FINANCIALS
8.5 Mio $ equity
1.6 non diluting + 3.2 open
ongoing convertible loan 4 Mio $
two future equity rounds 20 Mio $
expected exit: 2021/22

NEXT MILESTONES
TOP-N53 end toxicology Q2/18
IND Q4/18
FIH Q1/19
POC Q2/19

Problem & solution:
Chronic non-healing wounds and excessive scar formation

Wound healing
TOP-N53

Scar & keloid prev.
TOP-N44

Glaucoma
TOP-N73a

USP:
Dual mode of action
Increasing blood flow
Potency & efficacy
Breakthrough potential
IND preparation

USP:
Dual mode of action
Anti fibrotic drug
Unique efficacy in animal models
Preclinical

USP:
Dual mode of action
IOP lowering, increasing blood flow
Neuroprotection
Preclinical

© Topadur Pharma AG | October 2018
Key people committed to success

Leadership and board >150 years Pharma R&D

**Leadership**

- **Dr. Guido Koch**
  - COO & Development

- **Dr. Hermann Tenor**
  - Medical R&D

- **Christina Attaalla**
  - Finance, HR, Legal

**Board**

- **Dr. Reto Naef**
  - CEO & President

- **Dr. Reinhard Ambros**
  - VC, BD&L

- **Prof. Dr. Günther Wess**
  - Helmholz, R&D, diabetes

- **Harry Welten**
  - Exp. CFO, finance strategy

- **Dr. Armin Meinzer**
  - Secretary o. B.

- **Dr. Dominik Escher**
  - Serial founder, deal making

- **Pascal Brenneisen**
  - HP, investor, legal, market

© Topadur Pharma AG | October 2018
**Development drug pipeline and platform**

### Wound healing
**TOP-N53**
1st priority
- Diabetic foot ulcers
- Orphan ulcers
- Decubitus
- Major surgery (incl. bone)
- Dental surgery

### Ocular blood flow
**TOP-N73a**
2nd priority
- Glaucoma
- 2. AMD
- 3. Diabetic Retinopathy

### Scar & keloid prevention
**TOP-N44**
3rd priority
- Burn wounds
- Skin fibrosis
- Scleroderma
- Cosmetic surgery

### Opportunistic Projects
**TOP-N73b-d**
- 1. ED - Topical
- 2. Pulmonary Arterial Hypertension
- 3. Medical Cosmetics

© Topadur Pharma AG | October 2018
Diabetic foot ulcer & chronic wounds

- Leading cause of hospitalizations in diabetes
- 50 million patients hospitalized p.a.
- Huge cost burden ($12 bn p.a.)
- Market will double in 15 years

Current Therapies (limited success)
- Negative pressure
- Skin substitutes
- Oxygen
- Growth factors
- Regranex (Becaplermin)

- 1 million foot amputations p.a.
- 5 year survival 21%
Milestones for Top-N53 and US Approvals

- **TOP-N53**
  - 2009: Drug discovery
  - 2010: EU Patent filing
  - 2011: POC In vitro
  - 2012: POC in vivo (animals)
  - 2013: GMP drug prod
  - 2014: Toxicology
  - 2015: FIH
  - 2016: POC human
  - 2017: Phase I/IIa
  - 2018: Phase IIb/III
  - 2019: EU Patent filing
  - 2020: Global filing
  - 2021: IND* appl
  - 2022: Approval orphan indication
  - 2023: Approv. DFU Wagner > 3
  - 2024: Approv. DFU Wagner < 3
  - 2025: Approv. other Wound healing
  - 2026: Wound healing

* Investigational New Drug
## Financing Strategy

<table>
<thead>
<tr>
<th></th>
<th>In vitro profile</th>
<th>2 POC animal</th>
<th>first in human</th>
<th>POC human</th>
<th>Phase 1/2</th>
<th>Exit Trade sale IPO</th>
<th>Orphan 1st launch</th>
<th>DFU Phase 3</th>
<th>DFU 1st launch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-diluting financing Out-licensing</td>
<td>500</td>
<td>1’000</td>
<td>3’500</td>
<td>1’000</td>
<td>4’000</td>
<td>190’000</td>
<td>50’000</td>
<td>50’000</td>
<td></td>
</tr>
<tr>
<td>FTEs</td>
<td>4</td>
<td>8</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>20</td>
<td>30</td>
<td>45</td>
<td>70</td>
</tr>
<tr>
<td>General expenses</td>
<td>-200</td>
<td>-1’800</td>
<td>-2’500</td>
<td>-3’800</td>
<td>-6’400</td>
<td>-8’800</td>
<td>-19’800</td>
<td>-29’700</td>
<td>-44’500</td>
</tr>
<tr>
<td>Equity financing</td>
<td>300</td>
<td>2’200</td>
<td>6’100</td>
<td>4.500*</td>
<td>12’000*</td>
<td>13’500**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Company valuation</td>
<td>0.1-2</td>
<td>7-10</td>
<td>19-25</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
</tbody>
</table>

* Ser C: 4.5 Mio. Convertible loan after completed toxicology program mid 2018 (done)+6-8 Mio. $ mid 2019
** Ser D: up to 13.5 Mio. Reduced depending on non diluting financing
• Discovered a new type of drugs with unique potency and efficacy, dual mode of action

• TOP-N53 leading development drug to enable healing of chronic wounds

• Full pipeline

• Strong IP

• Experienced leadership team and board

• Productive collaborations with academic leaders in their field

• Enormous market potential
AWARDS

- Winners Pitching Battle CEO day 2015
- Finalist Swiss Innovation Challenge 2015
- Winner Venture Leaders Life Science 2016
- Top 100 Swiss Startups 2016
- CTI label company 2016

- Winner IMD Startup 2016
- Top 100 Swiss Startups 2017
- Winner Swiss Innovation Challenge 2017
- Winner Venture Leaders China 2018
- Winner SEF high-tech Award 2018
- Top 100 Swiss Startups 2018